In Vitro Activities of Rabeprazole, a Novel Proton Pump Inhibitor, and Its Thioether Derivative Alone and in Combination with Other Antimicrobials Against Recent Clinical Isolates of Helicobacter Pylori

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2000 Jan 20

PMID 10639386

Citations 11

Authors

Y Kawakami

T Akahane

M Yamaguchi

K Oana

Y Takahashi

Y Okimura

T Okabe

A Gotoh

T Katsuyama

Affiliations

Soon will be listed here.

Abstract

The MICs of rabeprazole sodium (RPZ), a newly developed benzimidazole proton pump inhibitor (PPI), against 133 clinical Helicobacter pylori strains revealed a higher degree of activity than the another two PPIs, lansoprazole and omeprazole. Time-kill curve assays of RPZ, when combined with amoxicillin, clarithromycin, or metronidazole, disclosed that synergistic effects were demonstrated in combination with each antibiotic examined. Moreover, no apparent antagonistic effect appeared among all of the strains tested.

Citing Articles

Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.

Han Y, Zhou L, Hu Y, Ding X, Long H, Liu F J Gastroenterol. 2023; 58(12):1167-1177.

PMID: 37777987 DOI: 10.1007/s00535-023-02042-2.

The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Eradication: An Open-Label Random Trial.

Chen L, Chang L, Hua C, Liu C, Chou T, Lin C J Clin Med. 2021; 10(19).

PMID: 34640370 PMC: 8509452. DOI: 10.3390/jcm10194352.

A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.

Yu L, Sun L, Zhang X, Li Y, Yu L, Yuan Z Adv Ther. 2017; 34(5):1070-1086.

PMID: 28429247 PMC: 5427147. DOI: 10.1007/s12325-017-0532-9.

Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.

Miftahussurur M, Yamaoka Y Molecules. 2015; 20(4):6068-92.

PMID: 25856059 PMC: 6272313. DOI: 10.3390/molecules20046068.

High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.

Yang J, Lin C, Wang H, Chen J, Kao J, Shun C Clin Gastroenterol Hepatol. 2014; 13(5):895-905.e5.

PMID: 25460556 PMC: 4404168. DOI: 10.1016/j.cgh.2014.10.036.

References

Cloud M, Enas N, Humphries T, Bassion S . Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci. 1998; 43(5):993-1000. DOI: 10.1023/a:1018822532736. View

Gotoh A, Kawakami Y, Akamatsu T, Katsuyama T . Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. Microbiol Immunol. 1997; 41(11):865-9. DOI: 10.1111/j.1348-0421.1997.tb01942.x. View

Marshall B, Warren J . Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390):1311-5. DOI: 10.1016/s0140-6736(84)91816-6. View

Warren J, Marshall B . Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983; 1(8336):1273-5. View

Goodwin C . Duodenal ulcer, Campylobacter pylori, and the "leaking roof" concept. Lancet. 1988; 2(8626-8627):1467-9. DOI: 10.1016/s0140-6736(88)90942-7. View

Graham D, Go M . Helicobacter pylori: current status. Gastroenterology. 1993; 105(1):279-82. DOI: 10.1016/0016-5085(93)90038-e. View

Hirai M, Azuma T, Ito S, Kato T, Kohli Y . A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol. 1995; 30(4):461-4. DOI: 10.1007/BF02347561. View

Tsuchiya M, Imamura L, Park J, KOBASHI K . Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull. 1995; 18(8):1053-6. DOI: 10.1248/bpb.18.1053. View

Takimoto T, Ido K, Taniguchi Y, Satoh K, Saifuku K, Kihira K . Efficacy of lansoprazole in eradication of Helicobacter pylori. J Clin Gastroenterol. 1995; 20 Suppl 2:S121-4. DOI: 10.1097/00004836-199506002-00033. View

10.

Moayyedi P, Sahay P, Tompkins D, Axon A . Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol. 1995; 7(9):835-40. View

11.

Graham D, de Boer W, Tytgat G . Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol. 1996; 91(6):1072-6. View

12.

Markham A, McTavish D . Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs. 1996; 51(1):161-78. DOI: 10.2165/00003495-199651010-00010. View

13.

Park J, Imamura L, KOBASHI K . Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull. 1996; 19(2):182-7. DOI: 10.1248/bpb.19.182. View

14.

Gotoh A, Kawakami Y, Akahane T, Akamatsu T, Shimizu T, Kiyosawa K . Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. Microbiol Immunol. 1997; 41(1):7-12. DOI: 10.1111/j.1348-0421.1997.tb01166.x. View

15.

. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut. 1997; 41(1):8-13. PMC: 1027220. DOI: 10.1136/gut.41.1.8. View

16.

Kawakami Y, Akahane T, Gotoh A, Okimura Y, Oana K, Katsuyama T . Successful development of air-dried microplates (HP-Plates) for susceptibility testing against Helicobacter pylori isolates. Microbiol Immunol. 1997; 41(9):703-8. DOI: 10.1111/j.1348-0421.1997.tb01914.x. View

17.

Lind T, van Zanten S, Unge P, Spiller R, Bayerdorffer E, OMorain C . Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996; 1(3):138-44. DOI: 10.1111/j.1523-5378.1996.tb00027.x. View

18.

Stack W, Knifton A, Thirlwell D, Cockayne A, Jenkins D, Hawkey C . Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol. 1998; 93(10):1909-13. DOI: 10.1111/j.1572-0241.1998.00582.x. View